Approximately 6-month after CART19 the patient relapsed with a clonally related CD19-negative plasmablastic lymphoma (PBL) and a minor population of residual CD19-negative CLL. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.